"I can just put you on a treatment while I'm waiting to understand exactly what your situation is. I don't need to wait to get information back and classify you as drug sensitive, this or that regimen. There is no need to go through all of that."
"The hope of having a universal regimen that is shorter, that has less side-"
Globally, an estimated 10.7 million people contracted tuberculosis last year and 1.23 million died. TB remains a major global public-health problem and the leading infectious cause of death. Progress toward ending TB this decade is threatened by aid cuts and missed targets. Sorfequiline, a new antibiotic, showed stronger activity against TB bacteria than existing treatments with a comparable safety profile. A trial of 309 participants across 22 sites in South Africa, the Philippines, Georgia, Tanzania and Uganda tested different dose regimens in people with drug-sensitive TB. The trial suggested a sorfequiline-based universal regimen could shorten treatment by months, simplify care, and allow immediate treatment initiation without waiting for detailed diagnostic classification.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]